QDEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
QuidelOrtho is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The recent stock surge is driven by a possible asset sale and debt reduction story, but the stock has already run sharply and the fundamental outlook remains mixed. My direct view: hold off for now rather than buy immediately.
QDEL is in a short-term bullish recovery after a strong move, but the setup is not ideal for a fresh long-term entry. MACD histogram is positive and expanding, which supports upward momentum. However, RSI_6 at 77.32 suggests the stock is stretched after the recent rally. Moving averages are converging, which often signals an unstable trend rather than a clean breakout trend. Price at 18.24 is just below R1 at 18.576, so the stock is near resistance. The technical picture is constructive, but not attractive enough to chase at current levels.
["Recent reports that QuidelOrtho is considering selling its point-of-care testing business for around $1.5 billion, which could help reduce debt.", "Shares surged sharply on the divestiture news, showing strong near-term market interest.", "Insiders are buying, with insider buying up 2578.44% over the last month, which is a meaningful positive signal.", "MACD is positive and expanding, confirming short-term momentum."]
["The company still carries a heavy debt burden, with the news repeatedly highlighting leverage concerns.", "Analysts recently cut price targets sharply and several remain Neutral or Underweight.", "Jefferies called the Q1 report disappointing and said the 2026 outlook is aggressive.", "UBS expects the overhang to persist, and JPMorgan still has an Underweight rating.", "Options positioning is bearish with put-call ratios above 1.", "RSI indicates the stock is overextended after the rally, making the current entry less attractive."]
No usable latest-quarter financial snapshot was provided because the financial snapshot data returned an error. Based on the analyst commentary, the latest quarter appears to have been weak, with disappointing Q1 results, weak respiratory performance, and China policy headwinds. The market is currently focused more on debt reduction and restructuring than on clear operating growth.
Analyst sentiment has turned more cautious over the last few months. JPMorgan, UBS, Citi, and Jefferies all reduced price targets materially, and Jefferies downgraded the stock to Hold from Buy. The latest target change from JPMorgan was only a small increase to $12 from $11, but the firm still kept an Underweight rating. Overall, Wall Street pros lean negative to neutral: the main bullish argument is balance-sheet improvement from asset sales, while the bearish view is that operational weakness, China risk, and uncertain deleveraging still outweigh the upside.
